Home
Products
Learn
About
Pricing
Log In
NEU
Asset Logo

Neuren Pharmaceuticals Limited

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual capital growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

28
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The Company’s lead drug compound, Trofinetide, is in Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted Orphan Drug designation to Neuren for trofinetide in Rett syndrome. The firm has granted an exclusive license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America while retaining all rights outside North America. The firm is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.

📈 Performance

Price History

+2312.50%

1M

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$13.51

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in NEU

28

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in NEU

682 days
NEU investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

62%

Less than 50k

21%
👶 Age of investors

18 - 25

26 - 34

29%

35 - 90

68%
🙋 Legal gender of investors

Female

61%

Male

39%

Pearlers who invest in NEU also invest in...

Vanguard Australian Shares Index Etf

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

📊 Share price

$90.18 AUD

NULL AUSTRALIA

NULL BETA

Find Out More

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

📊 Share price

$104.08 AUD

NULL GLOBAL

NULL EX AUSTRALIA

NULL BETA

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

📊 Share price

$43.11 AUD

NULL US

NULL EX AUSTRALIA

NULL BETA

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

📊 Share price

$57.36 AUD

NULL GLOBAL

NULL SMART BETA

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Adelaide, South Australia. The company went IPO on 2011-02-11. The firm owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Sa Zinc, Jervois Domain, Blueys and Inkheart Lead/Silver, Bynoe Gold, Fitton Uranium, and Napperby Uranium. Shoobridge Lithium project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. Sa Zinc project covers a total area of approximately 500 km2 in northern South Australia. Jervois Domain project covers three exploration licenses in the central Northern Territory.

📊 Share price

$1.07 AUD

Want more shares? Try these...

NEUN

Compare
Add to watchlist